Search results
Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes
Medscape· 1 day agoReal-world study data suggest there is little difference among five drug classes commonly used to treat PsA in terms of their ability to improve both joint and skin symptoms.
Best 16 Amazon Prime Perks You Might Not Know About
CNET· 11 hours agoAs an Amazon Prime member, you probably make frequent use of the free 2-day shipping. Below, we're going to break down some Amazon Prime perks you might...
Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Increases By 156.6%
ETF DAILY NEWS· 6 days ago180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) was the target of a significant growth in...
Roger Goodell Throws His Own Network Under The Bus During ‘Sunday Ticket’ Testimony
Sports Illustrated· 2 days agoA group of "Sunday Ticket" subscribers filed an antitrust lawsuit against the NFL for selling the...
Hyperbaric oxygen enhances tumor penetration and accumulation of engineered bacteria for synergistic...
Nature· 3 days agoDelivering bacteria-based drug for cancer therapy is limited by their penetration into extracellular matrix (ECM). Here the authors report effective depletion of ECM with hyperbaric oxygen therapeutic ...
NFL great JJ Watt reacts to TY Hilton's son commitment to Wisconsin: 'Happy to be rooting for a...
Fox News· 4 days agoFour-time NFL Pro Bowler T.Y. Hilton's Father's Day weekend got off to a memorable start. High...
Analysts mixed on pluses, minuses of HanesBrands sale of Champion
Winston-Salem Journal· 4 days agoHanesBrands Inc.’s pending $1.2 billion to $1.5 billion sale of its iconic global Champion brand —...
Netflix Seeking Production Partner to Air Christmas Games
GiveMeSport· 4 days agoFootball can be some of the best television in the world when it’s at its peak, so it shouldn’t be a...
Short Interest in UCB SA (OTCMKTS:UCBJY) Rises By 152.5%
ETF DAILY NEWS· 6 days agoUCB SA (OTCMKTS:UCBJY – Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 15,400 shares, a growth of 152.5% from ...
J&J's phase 2 Sjögren's data support FcRn strategy in the autoimmune disorder
FierceBiotech· 3 days agoThe unveiling of Johnson & Johnson’s full data from the phase 2 trial of nipocalimab in Sjögren's disease (SjD) suggest that both the Big Pharma and its competitor argenx are on the right track ...